These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 31402780)

  • 21. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
    Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
    Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
    Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
    Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
    Choi B; Lee JS; Kim SJ; Hong D; Park JB; Lee KY
    Cancer Lett; 2020 May; 478():56-69. PubMed ID: 32145342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
    Schofield DJ; Percival-Alwyn J; Rytelewski M; Hood J; Rothstein R; Wetzel L; McGlinchey K; Adjei G; Watkins A; Machiesky L; Chen W; Andrews J; Groves M; Morrow M; Stewart RA; Leinster A; Wilkinson RW; Hammond SA; Luheshi N; Dobson C; Oberst M
    MAbs; 2021; 13(1):1857100. PubMed ID: 33397194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
    Front Immunol; 2019; 10():454. PubMed ID: 30967859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 31. The potential application of PD-1 blockade therapy for early-stage biliary tract cancer.
    Umemoto K; Togashi Y; Arai Y; Nakamura H; Takahashi S; Tanegashima T; Kato M; Nishikawa T; Sugiyama D; Kojima M; Gotohda N; Kuwata T; Ikeda M; Shibata T; Nishikawa H
    Int Immunol; 2020 Apr; 32(4):273-281. PubMed ID: 31867666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status.
    Ashizawa T; Iizuka A; Maeda C; Tanaka E; Kondou R; Miyata H; Sugino T; Kawata T; Deguchi S; Mitsuya K; Hayashi N; Asai A; Ito M; Yamaguchi K; Akiyama Y
    Immunol Lett; 2019 Dec; 216():43-50. PubMed ID: 31586551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent updates on Sintilimab in solid tumor immunotherapy.
    Liu X; Yi Y
    Biomark Res; 2020 Dec; 8(1):69. PubMed ID: 33292551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
    Freeman ZT; Nirschl TR; Hovelson DH; Johnston RJ; Engelhardt JJ; Selby MJ; Kochel CM; Lan RY; Zhai J; Ghasemzadeh A; Gupta A; Skaist AM; Wheelan SJ; Jiang H; Pearson AT; Snyder LA; Korman AJ; Tomlins SA; Yegnasubramanian S; Drake CG
    J Clin Invest; 2020 Mar; 130(3):1405-1416. PubMed ID: 32015231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
    Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
    MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
    Wang Z; Sun K; Xiao Y; Feng B; Mikule K; Ma X; Feng N; Vellano CP; Federico L; Marszalek JR; Mills GB; Hanke J; Ramaswamy S; Wang J
    Sci Rep; 2019 Feb; 9(1):1853. PubMed ID: 30755715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma.
    Cai Y; Wang F; Liu Q; Li Z; Li D; Sun Z
    Invest New Drugs; 2019 Oct; 37(5):799-809. PubMed ID: 30368626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.